首页|麻黄附子细辛汤联合孟鲁司特钠对咳嗽变异性哮喘症状改善及外周血树突状细胞mDCs和pDCs水平的影响

麻黄附子细辛汤联合孟鲁司特钠对咳嗽变异性哮喘症状改善及外周血树突状细胞mDCs和pDCs水平的影响

扫码查看
目的 分析麻黄附子细辛汤联合孟鲁司特钠对咳嗽变异性哮喘患儿症状改善及外周血髓样树突状细胞(mye-loid dendritic cells,mDCs)和浆细胞样树突状细胞(plasmacytoid dendritic cells,pDCs)及肺功能的影响.方法 选取医院22019年1月—2020年12月收治的132例咳嗽变异性哮喘患儿作为研究对象.按随机数字表法分为两组,对照组66例,在常规雾化治疗基础上给予孟鲁司特钠治疗;观察组66例,在对照组基础上给予麻黄附子细辛汤治疗.检测两组患儿治疗前、治疗后1、2、3、4周外周血mDCs、pDCs及mDCs/pDCs数据变化、症状改善情况及肺功能的影响.随访1年观察复发情况.结果 两组治疗前后外周血mDCs比例没有变化(P>0.05);两组治疗后外周血pDCs比例均持续下降(P<0.05),但观察组治疗后2周和3周外周血pDCs比例低于对照组(P<0.05);两组治疗后mDCs/pDCs比值升高(P<0.05),但观察组治疗后2周和3周的mDCs/pDCs比值高于对照组(P<0.05).治疗4周后,观察组早晚的咳嗽评分低于对照组(P<0.05);治疗4周后观察组肺功能各指标优于对照组(P<0.05);随访1年后,病例均未脱落,观察组复发率4.55%(3/66)低于对照组15.15%(10/66)(P<0.05).结论 麻黄附子细辛汤联合孟鲁司特钠治疗咳嗽变异性哮喘,更能快速降低外周血pDCs比例、提升mDCs/pDCs比值,有助于快速纠正患儿体内Th1/Th2的失衡状态同时减轻临床症状、优化肺功能,预后较好.
Effects of Mahuang Fuzi Xixin Decoction(麻黄附子细辛汤)Combined with Montelukast Sodium on Symptom Improvement and Levels of Dendritic Cell mDCs and pDCs in Peripheral Blood in Children with Cough Variant Asthma
Objective To analyze the effect of Mahuang Fuzi Xixin Decoction(麻黄附子细辛汤)combined with montelukast sodium on symptom improvement,the levels of myeloid dendritic cells(mDCs)and plasmacytoid dendritic cells(pDCs)in pe-ripheral blood and lung function after treatment.Methods A total of 132 children with cough variant asthma who were admitted to the hospital from January 2019 to December 2020 were selected as the research objects.They were divided into two groups ac-cording to random number table method.The control group(66 cases)received montelusna on the basis of conventional atomiza-tion therapy.The observation group(66 cases)were treated with Mahuang Fuzi Xixin Decoction based on the control group.The changes of mDCs and pDCs in peripheral blood and the ratio of mDCs/pDCs,symptom improvement and lung function of the two groups were detected before and after treatment at 1,2,3 and 4 weeks.The recurrence was observed after one year follow-up.Results There was no change in the proportion of mDCs in peripheral blood of the two groups before and after treatment(P>0.05).The proportion of pDCs in peripheral blood of both groups continued to decrease after treatment(P<0.05),but the pro-portion of pDCs in peripheral blood of the observation group was lower than that of the control group at 2 and 3 weeks after treat-ment(P<0.05).The ratio of mDCs/pDCs in the two groups increased after treatment(P<0.05),but the ratio of mDCs/pDCs in the observation group was higher than that of the control group at 2 and 3 weeks after treatment(P<0.05).After 4 weeks of treatment,the cough score of the observation group was lower than that of the control group(P<0.05).After 4 weeks of treat-ment,the indexes of lung function in the observation group were better than those in the control group(P<0.05).After one year of follow-up,all cases did not shed,and the recurrence rate of the observation group was 4.55%(3/66),lower than that of the control group[15.15%(10/66)](P<0.05).Conclusion Mahuang Fuzi Xixin Decoction combined with montelukast sodium in the treatment of cough variant asthma can more rapidly reduce the proportion of peripheral blood pDCs and increase the ratio of mDCs/pDCs,which is helpful to quickly correct the imbalance of Th1/Th2 in children and relieve clinical symptoms and optimize the lung function,and the prognosis is better.

Mahuang Fuzi Xixin Decoction(麻黄附子细辛汤)cough variant asthmamyeloid dendritic cellsplasmacytoid dendritic cellsmontelukast sodiumMontelukast Sodium

郭亚丽、李鹏飞、吴慧芬、张希、应春

展开 >

浙江中医药大学附属江南医院,浙江 杭州 311200

麻黄附子细辛汤 咳嗽变异性哮喘 髓样树突状细胞 浆细胞样树突状细胞 孟鲁司特钠

浙江省中医药科技计划项目

2015ZT006

2024

中华中医药学刊
中华中医药学会 ,辽宁中医药大学

中华中医药学刊

CSTPCD北大核心
影响因子:1.007
ISSN:1673-7717
年,卷(期):2024.42(10)